Endothelin antagonists are a relatively new class of compounds with manifold therapeutic potentials currently being explored.
Answers are grounded in this paper and cite their sources.
Endothelin antagonists merit cautious exploration across indications; leaves open any clinical role pending randomized trials.
With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.
No takes yet. Share an insight, caveat, or question.
Webb et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: